MinaPharm Pharmaceuticals
Quick facts
Marketed products
- Bon one in Arm 3
Bon one in Arm 3 is a medication that works by [insert mechanism here, if known] - Ciprodiazole · Other
- Ciprofloxacin Tablets & Metronidazole tablets · Infectious Disease
This combination product uses ciprofloxacin to inhibit bacterial DNA gyrase and topoisomerase IV, while metronidazole generates reactive intermediates that damage DNA in anaerobic microorganisms. - r-Hirudin · Cardiovascular
r-Hirudin is a recombinant direct thrombin inhibitor that prevents blood clot formation by blocking thrombin's ability to convert fibrinogen to fibrin. - Reiferon retard · Oncology, Virology/Infectious Disease
Reiferon retard is a long-acting formulation of interferon alfa-2a that activates innate and adaptive immune responses to inhibit viral replication and tumor cell growth. - Reiferon Retard in Arm 1 · Oncology, Virology
Reiferon Retard is a long-acting interferon alfa-2a that activates innate and adaptive immune responses to inhibit viral replication and tumor cell growth. - Ribavirin in Arm 1 · Virology/Infectious Disease
Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with the viral polymerase and depleting guanosine nucleotide pools. - UDCA 250mg
- Ursoplus · Other
- Xerovirinc in Arm 2
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about MinaPharm Pharmaceuticals
What are MinaPharm Pharmaceuticals's marketed drugs?
Top marketed products include Bon one in Arm 3, Ciprodiazole, Ciprofloxacin Tablets & Metronidazole tablets, r-Hirudin, Reiferon retard, Reiferon Retard in Arm 1.
Related
- Bon one in Arm 3
- Ciprodiazole · Other
- Ciprofloxacin Tablets & Metronidazole tablets · Infectious Disease
- r-Hirudin · Cardiovascular
- Reiferon retard · Oncology, Virology/Infectious Disease
- Sector hub: All tracked pharma companies